M 
Mediwelcome Healthcare Management & Technology 2159.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
1.64
+2.50%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥468.0m
FY2017FY2025
Net income
CN¥10.0m
FY2017FY2025
Free cash flow
CN¥2.5m
FY2017FY2025
Shareholders' equity
CN¥111.3m
FY2017FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥468.0m | CN¥275.6m | CN¥284.0m | CN¥277.2m | CN¥607.1m | CN¥370.5m | CN¥366.1m | CN¥299.0m | CN¥258.9m |
| Gross profit | CN¥94.7m | CN¥43.7m | CN¥25.6m | CN¥27.9m | CN¥80.2m | CN¥82.5m | CN¥81.3m | CN¥84.6m | CN¥71.4m |
| Research and development | CN¥27.9m | CN¥16.0m | CN¥28.0m | CN¥43.4m | CN¥16.0m | CN¥12.0m | CN¥9.9m | CN¥5.1m | CN¥4.0m |
| Operating income | CN¥1.8m | −CN¥31.0m | −CN¥81.8m | −CN¥83.2m | CN¥5.7m | CN¥24.8m | CN¥27.2m | CN¥49.6m | CN¥39.5m |
| Net income | CN¥10.0m | −CN¥38.8m | −CN¥80.6m | −CN¥76.5m | CN¥4.0m | CN¥18.0m | CN¥17.9m | CN¥38.0m | CN¥29.7m |
| Diluted earnings per share | 0.04 | -0.20 | -0.42 | -0.41 | 0.02 | 0.11 | 0.12 | 0.19 | 0.15 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥190.6m | CN¥166.3m | CN¥183.7m | CN¥272.4m | CN¥366.7m | CN¥240.0m | CN¥196.7m | CN¥203.2m | CN¥140.3m |
| Cash and short-term investments | CN¥99.4m | CN¥61.4m | CN¥68.9m | CN¥132.0m | CN¥174.8m | CN¥89.9m | CN¥78.5m | CN¥100.5m | CN¥95.2m |
| Total liabilities | CN¥85.1m | CN¥103.5m | CN¥80.9m | CN¥100.2m | CN¥73.2m | CN¥93.5m | CN¥72.6m | CN¥76.6m | CN¥41.5m |
| Debt | CN¥54.5m | CN¥40.9m | CN¥26.7m | CN¥22.7m | CN¥25.2m | CN¥21.8m | CN¥3.6m | CN¥8.1m | CN¥3.0m |
| Shareholders' equity | CN¥111.3m | CN¥61.0m | CN¥99.5m | CN¥167.1m | CN¥283.1m | CN¥138.1m | CN¥116.5m | CN¥118.9m | CN¥93.9m |
| Shares outstanding | 265m | 191m | 191m | 186m | 189m | 170m | 150m | 200m | 200m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥2.9m | −CN¥12.0m | −CN¥64.8m | −CN¥15.8m | CN¥224,552 | CN¥26.7m | CN¥3.9m | CN¥58.8m | −CN¥1.6m |
| Capital spending | −CN¥410,102 | −CN¥11.2m | −CN¥1.4m | −CN¥3.7m | −CN¥21.4m | −CN¥11.8m | −CN¥11.1m | −CN¥5.2m | −CN¥3.4m |
| Free cash flow | CN¥2.5m | −CN¥23.2m | −CN¥66.2m | −CN¥19.5m | −CN¥21.2m | CN¥14.8m | −CN¥7.3m | CN¥53.7m | −CN¥5.1m |
| Dividends paid | — | — | — | — | — | — | — | −CN¥13.8m | −CN¥13.8m |
Latest quarters
By quarter end
| Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Jun 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥227.7m | CN¥341.0m | CN¥127.1m | CN¥155.0m | CN¥120.6m | CN¥158.0m | CN¥125.9m | CN¥129.3m |
| Gross profit | CN¥68.8m | CN¥72.9m | CN¥21.8m | CN¥26.0m | CN¥17.7m | CN¥9.4m | CN¥16.2m | CN¥13.1m |
| Operating income | CN¥19.4m | CN¥5.6m | −CN¥3.8m | −CN¥11.7m | −CN¥19.4m | −CN¥35.6m | −CN¥34.7m | −CN¥39.7m |
| Net income | CN¥17.7m | CN¥16.1m | −CN¥6.1m | −CN¥19.7m | −CN¥19.0m | −CN¥50.1m | −CN¥30.5m | −CN¥36.8m |
| Diluted earnings per share | 0.08 | 0.06 | -0.02 | -0.10 | -0.10 | -0.26 | -0.16 | -0.20 |
| Cash from operations | CN¥20.0m | −CN¥16.0m | CN¥19.0m | −CN¥7.0m | −CN¥4.0m | −CN¥57.0m | −CN¥7.0m | −CN¥8.0m |
| Total assets | CN¥447.8m | CN¥190.6m | CN¥219.1m | CN¥166.3m | CN¥181.3m | CN¥183.7m | CN¥249.7m | CN¥272.4m |
| Cash and short-term investments | CN¥138.5m | CN¥99.4m | CN¥94.2m | CN¥61.4m | CN¥70.7m | CN¥68.9m | CN¥133.5m | CN¥132.0m |
| Debt | CN¥64.6m | CN¥52.0m | CN¥49.4m | CN¥40.9m | CN¥23.2m | CN¥26.7m | CN¥32.7m | CN¥22.7m |
| Shareholders' equity | CN¥129.8m | CN¥111.3m | CN¥64.2m | CN¥61.0m | CN¥83.8m | CN¥99.5m | CN¥135.8m | CN¥167.1m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 19.2% | 4.8% | — |
| Operating income | — | -40.7% | — |
| Net income | — | -11.1% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 18.6% | 14.7% | 15.5% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Price to earnings | 26.8 | -2.2 | -1.1 | -2.9 | 54.7 |
| Price to sales | 0.6 | 0.3 | 0.3 | 0.8 | 0.4 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.